IRIS Accounts Production v25.2.0.378 13216336 Board of Directors 31.12.24 1.1.24 31.12.24 31.12.24 Medium entities These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. The principal activities of the group are the provision of IT and telecommunications services, in particular recycling of metal waste and associated environmental services, including bio refining development. true true false true true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh132163362023-12-31132163362024-12-31132163362024-01-012024-12-31132163362022-12-31132163362023-01-012023-12-31132163362023-12-3113216336ns15:EnglandWales2024-01-012024-12-3113216336ns14:PoundSterling2024-01-012024-12-3113216336ns10:Director12024-01-012024-12-3113216336ns10:Consolidated2024-12-3113216336ns10:ConsolidatedGroupCompanyAccounts2024-01-012024-12-3113216336ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3113216336ns10:Consolidatedns10:MediumEntities2024-01-012024-12-3113216336ns10:Consolidatedns10:Audited2024-01-012024-12-3113216336ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3113216336ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3113216336ns10:Consolidated2024-01-012024-12-3113216336ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-01-012024-12-3113216336ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForAccounts2024-01-012024-12-3113216336ns10:FullAccounts2024-01-012024-12-311321633612024-01-012024-12-3113216336ns10:Director22024-01-012024-12-3113216336ns10:Director32024-01-012024-12-3113216336ns10:Director42024-01-012024-12-3113216336ns10:RegisteredOffice2024-01-012024-12-3113216336ns10:Director52024-01-012024-12-3113216336ns10:Consolidated2023-01-012023-12-3113216336ns5:CurrentFinancialInstruments2024-12-3113216336ns5:CurrentFinancialInstruments2023-12-3113216336ns5:ShareCapital2024-12-3113216336ns5:ShareCapital2023-12-3113216336ns5:SharePremium2024-12-3113216336ns5:SharePremium2023-12-3113216336ns5:RetainedEarningsAccumulatedLosses2024-12-3113216336ns5:RetainedEarningsAccumulatedLosses2023-12-3113216336ns5:ShareCapital2022-12-3113216336ns5:RetainedEarningsAccumulatedLosses2022-12-3113216336ns5:SharePremium2022-12-3113216336ns5:ShareCapital2024-01-012024-12-3113216336ns5:SharePremium2024-01-012024-12-3113216336ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-3113216336ns5:NetGoodwill2024-01-012024-12-3113216336ns5:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3113216336ns5:LeaseholdImprovements2024-01-012024-12-3113216336ns5:PlantMachinery2024-01-012024-12-3113216336ns5:FurnitureFittings2024-01-012024-12-3113216336ns5:MotorVehicles2024-01-012024-12-3113216336ns5:CostValuation2023-12-3113216336ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3113216336ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-31
REGISTERED NUMBER: 13216336 (England and Wales)











Group Strategic Report, Report of the Directors and

Consolidated Financial Statements

for the Year Ended 31 December 2024

for

Bio Scope 3 Ltd

Bio Scope 3 Ltd (Registered number: 13216336)






Contents of the Consolidated Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Group Strategic Report 2

Report of the Directors 5

Report of the Independent Auditors 7

Consolidated Income Statement 11

Consolidated Other Comprehensive Income 12

Consolidated Balance Sheet 13

Company Balance Sheet 14

Consolidated Statement of Changes in Equity 15

Company Statement of Changes in Equity 16

Consolidated Cash Flow Statement 17

Notes to the Consolidated Cash Flow Statement 18

Notes to the Consolidated Financial Statements 19


Bio Scope 3 Ltd

Company Information
for the Year Ended 31 December 2024







DIRECTORS: A C T Gomarsall
J A Gomarsall
N J Razey
S Taylor



REGISTERED OFFICE: Eldo House
Kempson Way
Suffolk Business Park
Bury St Edmunds
Suffolk
IP32 7AR



REGISTERED NUMBER: 13216336 (England and Wales)



SENIOR STATUTORY AUDITOR: James Knights FCA ACA



AUDITORS: Knights Lowe Limited
Eldo House
Kempson Way
Suffolk Business Park
Bury St Edmunds
Suffolk
IP32 7AR

Bio Scope 3 Ltd (Registered number: 13216336)

Group Strategic Report
for the Year Ended 31 December 2024

The directors present their strategic report of the company and the group for the year ended 31 December 2024.

1. Business Overview

Bio Scope 3 Limited ("Bio 3") is the holding company for the Bio Scope 3 group of companies ("the Group"), which includes two trading subsidiary companies, Network 2 Supplies Limited ("n2s") and Bio Scope Technologies Limited ("Bio Tech").


n2s is an industry leader in IT Lifecycle Management with specialist expertise in the sustainability, security and compliance challenges associated with technology. The company's mission is to redefine the lifecycle of technology pioneering innovations such as in precious metal recovery to achieve circularity in the IT and telecoms sectors. n2s is the first technology lifecycle management provider with expertise in decarbonisation to truly empower SME and large enterprise businesses to deliver and report on their IT sustainability goals.Bio Tech has invested in considerable Research & Development knowledge and expertise, combined with comprehensive laboratory and production testing processes.

2. Objectives and Strategy
Group Objectives:
- To double revenues and significantly increase financial profitability over the next three years
- To work in collaboration with strategic partners to supply products and materials for sustainable
recycling development projects
- To develop the recycling capabilities of its facility based in the Midlands
- To implement manageable value streams to determine the strengths and weaknesses of the business
- To develop and productionise bio leaching technologies

Group Strategy:
To achieve these objectives, Bio 3 is:
- Strengthening its marketing position by employing an agency to undertake this on its behalf
- Employing a science team with the knowledge to implement our company objectives for Bio Tech
- Enhancing customer support and post-sale engagement through a new CRM system and the introduction of
a Customer Operations team

REVIEW OF BUSINESS
Performance Summary:
Revenues reduced slightly to £12.8 million in 2024, compared to £13.1 million in 2023, driven primarily by a lack of significant one-off high revenue projects that were seen in previous years, ultimately resulting in an Operating Loss of £2.9 million in 2024 compared to an Operating Loss of £1.8 million achieved in 2023.

Key Performance Indicators (KPIs):
- Revenue growth: (-2%)
- Gross profit margin: 33%
- Customer retention rate: 86%
- New business: 8%


Bio Scope 3 Ltd (Registered number: 13216336)

Group Strategic Report
for the Year Ended 31 December 2024

PRINCIPAL RISKS AND UNCERTAINTIES
Principal Risks and Uncertainties

Risk Description Mitigation

Supply Chain Disruption
Increased lead times for
international deliveries
Increased upfront payment and
improved insurance policy

Regulatory Changes
Environment Agency permit
issuance
Work closely with local authorities to
ensure compliance

Cybersecurity
Data breaches or ransomware
attacks
Upgraded IT systems, regular staff
training, external audits

Intellectual Property
Competitors replicating our
developed technologies

Patents applied for



Environmental, Social and Governance (ESG)

Environmental:
The Group reduced its carbon emissions year-on-year by switching to renewable energy at all its facilities.

Social:
The Group introduced a new employee wellness programme, including mental health support, and in addition partnered with its customers on environmental awareness initiatives.

Governance:
The board of directors of n2s and Bio Tech were enhanced in the second half of 2024 with the introduction of a new Chairman and non-executive director strengthening oversight and strategic decision-making.

Future Outlook
The Group anticipates growth in the data centre decommissioning sector and will focus its sales and marketing teams in securing business in this area. Expansion of its facility in the Midlands has enabled floorspace in its Bury St Edmunds facility to be freed up for further revenue generating opportunities.

Significant funding of capital equipment to allow the implementation of bio leaching at full production scale.
Investments planned for 2025 include upgrading of site security and stock management systems throughout the business.

.


Bio Scope 3 Ltd (Registered number: 13216336)

Group Strategic Report
for the Year Ended 31 December 2024

SECTION 172(1) STATEMENT
The directors of Bio Scope 3 Limited have acted in good faith to promote the success of the company for the benefit of its members, and in doing so have considered:

Long-term impact: All major decisions, including investment in automation and expansion, are assessed
for long-term financial and environmental sustainability.
Employees: Regular town-hall meetings and anonymous surveys are used to engage employees and shape
HR policy.
Business relationships: Strategic partnerships with key customers are nurtured through quarterly reviews
and shared KPIs.
High standards of conduct: Regular review and update of Code of Conduct and whistleblowing policies.

ON BEHALF OF THE BOARD:





S Taylor - Director


26 September 2025

Bio Scope 3 Ltd (Registered number: 13216336)

Report of the Directors
for the Year Ended 31 December 2024

The directors present their report with the financial statements of the company and the group for the year ended 31 December 2024.

DIVIDENDS
No dividends will be distributed for the year ended 31 December 2024.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 January 2024 to the date of this report.

A C T Gomarsall
J A Gomarsall
N J Razey
S Taylor

Other changes in directors holding office are as follows:

P Allington - resigned 7 August 2024

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

Bio Scope 3 Ltd (Registered number: 13216336)

Report of the Directors
for the Year Ended 31 December 2024


AUDITORS
The auditors, Knights Lowe Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





S Taylor - Director


26 September 2025

Report of the Independent Auditors to the Members of
Bio Scope 3 Ltd

Opinion
We have audited the financial statements of Bio Scope 3 Ltd (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the group's and of the parent company affairs as at 31 December 2024 and of the group's loss for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Bio Scope 3 Ltd


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page five, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Bio Scope 3 Ltd


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with directors and other management, and from our commercial knowledge and experience of the companies operating sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:
- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud;
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:
- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias;
- investigated the rationale behind significant or unusual transactions; and
- specifically tested the used stock valuation including the used stock write-down provision, maintenance contracts, and the buy-back provision. These are areas requiring some level of management judgement and so could be susceptible to management bias.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:
- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims;
- reviewing correspondence with HMRC, relevant regulators [Scania for franchise purposes] and the company's legal advisors.


Report of the Independent Auditors to the Members of
Bio Scope 3 Ltd

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




James Knights FCA ACA (Senior Statutory Auditor)
for and on behalf of Knights Lowe Limited
Eldo House
Kempson Way
Suffolk Business Park
Bury St Edmunds
Suffolk
IP32 7AR

26 September 2025

Bio Scope 3 Ltd (Registered number: 13216336)

Consolidated
Income Statement
for the Year Ended 31 December 2024

2024 2023
as restated
Notes £    £    £    £   

TURNOVER 12,809,627 13,068,309

Cost of sales 8,586,057 8,230,736
GROSS PROFIT 4,223,570 4,837,573

Exceptional Items 160,376 -
Administrative expenses 7,076,711 6,615,323
7,237,087 6,615,323
(3,013,517 ) (1,777,750 )

Other operating income 107,697 -
OPERATING LOSS 4 (2,905,820 ) (1,777,750 )

Interest receivable and similar income - 34,519
(2,905,820 ) (1,743,231 )

Interest payable and similar expenses 6 349,959 282,248
LOSS BEFORE TAXATION (3,255,779 ) (2,025,479 )

Tax on loss 7 (39,911 ) 41,419
LOSS FOR THE FINANCIAL YEAR (3,215,868 ) (2,066,898 )
Loss attributable to:
Owners of the parent (2,502,637 ) (2,066,898 )
Non-controlling interests (713,231 ) -
(3,215,868 ) (2,066,898 )

Bio Scope 3 Ltd (Registered number: 13216336)

Consolidated
Other Comprehensive Income
for the Year Ended 31 December 2024

2024 2023
as restated
Notes £    £   

LOSS FOR THE YEAR (3,215,868 ) (2,066,898 )


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR THE
YEAR

(3,215,868

)

(2,066,898

)
Note
Prior year adjustment 9 (34,536 )
TOTAL COMPREHENSIVE INCOME SINCE LAST
ANNUAL REPORT

(3,250,404

)

Total comprehensive income attributable to:
Owners of the parent (2,537,223 ) (2,066,898 )
Non-controlling interests (713,181 ) -
(3,250,404 ) (2,066,898 )

Bio Scope 3 Ltd (Registered number: 13216336)

Consolidated Balance Sheet
31 December 2024

2024 2023
as restated
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 2,624,506 3,061,875
Tangible assets 11 2,957,300 2,433,779
Investments 12 - -
5,581,806 5,495,654

CURRENT ASSETS
Stocks 13 940,182 462,005
Debtors 14 3,032,465 2,345,748
Cash at bank and in hand 422,426 659,472
4,395,073 3,467,225
CREDITORS
Amounts falling due within one year 15 9,204,371 7,111,459
NET CURRENT LIABILITIES (4,809,298 ) (3,644,234 )
TOTAL ASSETS LESS CURRENT LIABILITIES 772,508 1,851,420

CREDITORS
Amounts falling due after more than one
year

16

(57,119

)

(160,252

)

PROVISIONS FOR LIABILITIES 19 (198,729 ) (238,640 )
NET ASSETS 516,660 1,452,528

CAPITAL AND RESERVES
Called up share capital 20 12 11
Share premium 21 6,279,943 3,999,994
Retained earnings 21 (5,050,114 ) (2,547,477 )
SHAREHOLDERS' FUNDS 1,229,841 1,452,528

NON-CONTROLLING INTERESTS 22 (713,181 ) -
TOTAL EQUITY 516,660 1,452,528

The financial statements were approved by the Board of Directors and authorised for issue on 26 September 2025 and were signed on its behalf by:





S Taylor - Director


Bio Scope 3 Ltd (Registered number: 13216336)

Company Balance Sheet
31 December 2024

2024 2023
as restated
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 - -
Tangible assets 11 - -
Investments 12 4,000,104 4,000,104
4,000,104 4,000,104

CURRENT ASSETS
Debtors 14 6,527,746 4,303,747

CREDITORS
Amounts falling due within one year 15 5,516,759 4,303,846
NET CURRENT ASSETS/(LIABILITIES) 1,010,987 (99 )
TOTAL ASSETS LESS CURRENT LIABILITIES 5,011,091 4,000,005

CAPITAL AND RESERVES
Called up share capital 20 12 11
Share premium 5,289,993 3,999,994
Retained earnings (278,914 ) -
SHAREHOLDERS' FUNDS 5,011,091 4,000,005

Company's loss for the financial year (278,914 ) -

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 26 September 2025 and were signed on its behalf by:





S Taylor - Director


Bio Scope 3 Ltd (Registered number: 13216336)

Consolidated Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up
share Retained Share
capital earnings premium
£    £    £   
Balance at 1 January 2023 11 (480,579 ) 3,999,994

Changes in equity
Deficit for the year - (2,032,362 ) -
Total comprehensive income - (2,032,362 ) -
Balance at 31 December 2023 11 (2,512,941 ) 3,999,994
Prior year adjustment - (34,536 ) -
As restated 11 (2,547,477 ) 3,999,994

Changes in equity
Deficit for the year - (2,502,637 ) -
Other comprehensive income - - -
Total comprehensive income - (2,502,637 ) -
Issue of share capital 1 - 2,279,949
Balance at 31 December 2024 12 (5,050,114 ) 6,279,943
Non-controlling Total
Total interests equity
£    £    £   
Balance at 1 January 2023 3,519,426 - 3,519,426

Changes in equity
Deficit for the year (2,032,362 ) - (2,032,362 )
Total comprehensive income (2,032,362 ) - (2,032,362 )
Balance at 31 December 2023 1,487,064 - 1,487,064
Prior year adjustment (34,536 ) - (34,536 )
As restated 1,452,528 - 1,452,528

Changes in equity
Deficit for the year (2,502,637 ) (713,231 ) (3,215,868 )
Other comprehensive income - 50 50
Total comprehensive income (2,502,637 ) (713,181 ) (3,215,818 )
Issue of share capital 2,279,950 - 2,279,950
Balance at 31 December 2024 1,229,841 (713,181 ) 516,660

Bio Scope 3 Ltd (Registered number: 13216336)

Company Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up
share Retained Share Total
capital earnings premium equity
£    £    £    £   
Balance at 1 January 2023 11 - 3,999,994 4,000,005

Changes in equity
Balance at 31 December 2023 11 - 3,999,994 4,000,005

Changes in equity
Issue of share capital 1 - 1,289,999 1,290,000
Total comprehensive income - (278,914 ) - (278,914 )
Balance at 31 December 2024 12 (278,914 ) 5,289,993 5,011,091

Bio Scope 3 Ltd (Registered number: 13216336)

Consolidated Cash Flow Statement
for the Year Ended 31 December 2024

2024 2023
as restated
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 (3,061,873 ) (1,022,646 )
Interest paid (399,347 ) (158,825 )
Interest element of hire purchase payments
paid

(19,691

)

(19,816

)
Net cash from operating activities (3,480,911 ) (1,201,287 )

Cash flows from investing activities
Purchase of tangible fixed assets (1,202,340 ) (986,592 )
Sale of tangible fixed assets 34,524 22,896
Interest received - (17 )
Net cash from investing activities (1,167,816 ) (963,713 )

Cash flows from financing activities
Capital repayments in year (215,116 ) (172,799 )
Amount introduced by directors 4,559,900 2,263,797
Share issue 2 -
Hire purchase interest 19,691 (19,199 )
New hire purchase agreements 47,204 148,883
Net cash from financing activities 4,411,681 2,220,682

(Decrease)/increase in cash and cash equivalents (237,046 ) 55,682
Cash and cash equivalents at beginning of
year

2

659,472

603,790

Cash and cash equivalents at end of year 2 422,426 659,472

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Cash Flow Statement
for the Year Ended 31 December 2024

1. RECONCILIATION OF LOSS BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

2024 2023
as restated
£    £   
Loss before taxation (3,255,779 ) (2,025,479 )
Depreciation charges 1,090,214 1,030,390
(Profit)/loss on disposal of fixed assets (8,549 ) 6,659
Minority interest 51 -
Finance costs 349,959 282,248
Finance income - (34,519 )
(1,824,104 ) (740,701 )
Increase in stocks (478,177 ) (178,171 )
Increase in trade and other debtors (686,717 ) (1,134,321 )
(Decrease)/increase in trade and other creditors (72,875 ) 1,030,547
Cash generated from operations (3,061,873 ) (1,022,646 )

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 December 2024
31.12.24 1.1.24
£    £   
Cash and cash equivalents 422,426 659,472
Year ended 31 December 2023
31.12.23 1.1.23
as restated
£    £   
Cash and cash equivalents 659,472 603,790


3. ANALYSIS OF CHANGES IN NET FUNDS

At 1.1.24 Cash flow At 31.12.24
£    £    £   
Net cash
Cash at bank and in hand 659,472 (237,046 ) 422,426
659,472 (237,046 ) 422,426
Debt
Finance leases (342,053 ) 148,221 (193,832 )
(342,053 ) 148,221 (193,832 )
Total 317,419 (88,825 ) 228,594

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Bio Scope 3 Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

In preparing the separate financial statements of Bio Scope 3 Ltd, advantage has been taken of the following disclosure exemptions available in FRS 102 on the basis the information is included in the consolidated financial statements:

- financial instrument disclosures (except for intercompany balances), including:
- categories of financial instruments;
- items of income, expenses, gains or losses relating to financial instruments; and
- exposure to and management of financial risks;
- share-based payment disclosures.

Basis of consolidation
The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Group (its subsidiaries). Control is achieved where the Group has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. Accounting policies consistent with those of the parent are used and all intra-group transactions, balances, income and expenses are eliminated in full on consolidation.

The consolidated financial statements incorporate the results of business combinations using the purchase method as outlined in the business combination policy in the note below. The results of acquired operations are included in the Consolidated Statement of Comprehensive Income from the date on which control is obtained. They are deconsolidated from the date control ceases.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover represents the sales value of work completed at the balance sheet date excluding VAT. The Group's contractual obligations are performed over time therefore revenue is recognised as the contract activity progresses to reflect the Group's partial performance of its contractual obligations. Revenue is calculated by reference to the value of work performed.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2021, is being amortised evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Leasehold property costs - 10% on cost and 10% straight line
Plant and machinery - 10 - 25% on reducing balance and 25% on reducing balance
Equipment - 15% on reducing balance
Motor vehicles - 25% on reducing balance and Straight line over 7 years

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stocks
There are three different types of stock the company hold valued as follows:

Scrap Materials
This is weighed at year-end and a conservative scrap material price is used based on the current London Metal Exchange prices.

Resale Stock
This is second hand computer equipment for resale. The second hand computer equipment market can have variable prices due to demand and management use their judgement to set an estimated sales prices based on market conditions as at the year-end date. Then 25% of this is taken as the deemed purchase price for stock which is generally obtained from site clearances.

Any purchased stock is shown at the lower of cost and net realisable value.

Any items which become obsolete due to advances in technology are written down on a quarterly basis.

Work In Progress
This is resale stock from site clearances yet to pass testing to ensure it is of an acceptable standard for resale. Management will still use their judgement to set an estimated sales price based on market conditions as at the year-end date. Then 25% of this is taken as the deemed purchase price.

Stock which passes testing will go into resale stock and the deemed purchase price increased to 60% of estimated sales price. Stock which is not of an acceptable standard for resale will be scrapped for minimal value.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

Government grants
Government grants in respect of capital expenditure are credited to the profit and loss account over the estimated useful life of the relevant fixed assets. The grants shown in the balance sheet represent the total grants receivable to date less the amount so far credited to the profit and loss account. The grants re conditional and in certain circumstances repayment of all or part of the grant may be required.

Grants of a revenue nature are credited to the profit and loss account in the accounting period in which they are receivable. If they relate to future periods an appropriate amount is deferred to future periods.

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Business combinations
Acquisitions of subsidiaries and businesses are accounted for using the purchase method. The cost of the business combination is measured at the aggregate of the fair values (at the date of exchange) of assets given, liabilities incurred or assumed, and equity instruments issued by the Group in exchange for control of the acquire, plus costs directly attributable to the business combination.

Any excess of the cost of the business combination over the Group’s interest in the net fair value of the identifiable assets and liabilities is recognised as goodwill.

For the purpose of impairment testing, the goodwill acquired in a business combination is allocated, on acquisition date, to the cash generating units that are expected to benefit from the synergies of the combination.

Contingent consideration is included in the cost of the combination at the acquisition date if additional payment(s) is(are) probable and can be measured reliably. The liability is measured at the present value of the estimated future payment(s), using a discount rate reflecting conditions at the acquisition date. If the additional payment becomes probable and/or reliably measurable only after the acquisition date it is recognised as an adjustment to the cost of the combination and goodwill at that time. Similarly, if estimated future payments are revised, for example due to the non-occurrence of future events that had been expected to occur, the resulting adjustment is recorded against goodwill. However, changes resulting from the unwinding of the discount are recognised in profit or loss.

Going Concern
Having reviewed the projected results and cash flow forecasts of the Group the directors are confident that the Group will be able to meet its cash obligations in the foreseeable future. Whilst there is always considerable uncertainty in predicting cash flows more than a few months into the future, the directors are confident that the cash demands of the company will be satisfied, and it is therefore appropriate to prepare the financial statements on the going concern basis.

As set out in the share capital note since the balance sheet date the shareholders have swapped debt for equity and refinanced the Group. They have confirmed their continued support for the Group for a period of at least twelve months from the date of approving these financial statements.

Investment in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

3. EMPLOYEES AND DIRECTORS
2024 2023
as restated
£    £   
Wages and salaries 4,881,349 4,458,959
Social security costs 503,787 442,951
Other pension costs 213,837 181,560
5,598,973 5,083,470

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

3. EMPLOYEES AND DIRECTORS - continued

The average number of employees during the year was as follows:
2024 2023
as restated

Direct 90 91
Sales 4 3
Administration and management 39 37
133 131

2024 2023
as restated
£    £   
Directors' remuneration 672,900 544,930
Directors' pension contributions to money purchase schemes 62,027 37,331

Information regarding the highest paid director is as follows:
2024 2023
as restated
£    £   
Emoluments etc 143,000 155,000
Pension contributions to money purchase schemes 2,202 2,201

4. OPERATING LOSS

The operating loss is stated after charging/(crediting):

2024 2023
as restated
£    £   
Hire of plant and machinery 7,568 10,564
Other operating leases 906,519 905,329
Depreciation - owned assets 551,158 456,032
Depreciation - assets on hire purchase contracts 101,686 130,036
(Profit)/loss on disposal of fixed assets (8,549 ) 6,659
Goodwill amortisation 437,369 437,405
Auditors' remuneration 38,003 16,990
Foreign exchange differences (894 ) 8,540

5. EXCEPTIONAL ITEMS

The exceptional items disclosed relate to severance payments made in the year.

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

6. INTEREST PAYABLE AND SIMILAR EXPENSES
2024 2023
as restated
£    £   
Other interest 51,354 4,994
Loan interest 278,914 257,438
Hire and lease purchase
interest 19,691 19,816
349,959 282,248

7. TAXATION

Analysis of the tax (credit)/charge
The tax (credit)/charge on the loss for the year was as follows:
2024 2023
as restated
£    £   
Deferred tax (39,911 ) 41,419
Tax on loss (39,911 ) 41,419

8. INDIVIDUAL INCOME STATEMENT

As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.


9. PRIOR YEAR ADJUSTMENT

The prior year adjustment relates to the correction of the interest rate on the loan from shareholders.

10. INTANGIBLE FIXED ASSETS

Group
Goodwill
£   
COST
At 1 January 2024
and 31 December 2024 4,399,720
AMORTISATION
At 1 January 2024 1,337,845
Amortisation for year 437,369
At 31 December 2024 1,775,214
NET BOOK VALUE
At 31 December 2024 2,624,506
At 31 December 2023 3,061,875

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

11. TANGIBLE FIXED ASSETS

Group
Leasehold
property Plant and Motor
costs machinery Equipment vehicles Totals
£    £    £    £    £   
COST
At 1 January 2024 390,084 2,539,018 110,729 881,433 3,921,264
Additions 137,086 918,342 113,912 33,000 1,202,340
Disposals - (44,814 ) - (69,135 ) (113,949 )
At 31 December 2024 527,170 3,412,546 224,641 845,298 5,009,655
DEPRECIATION
At 1 January 2024 79,423 928,447 44,587 435,028 1,487,485
Charge for year 41,006 468,509 26,066 117,263 652,844
Eliminated on disposal - (28,539 ) - (59,435 ) (87,974 )
At 31 December 2024 120,429 1,368,417 70,653 492,856 2,052,355
NET BOOK VALUE
At 31 December 2024 406,741 2,044,129 153,988 352,442 2,957,300
At 31 December 2023 310,661 1,610,571 66,142 446,405 2,433,779

Fixed assets, included in the above, which are held under hire purchase contracts are as follows:
Leasehold
property Plant and Motor
costs machinery vehicles Totals
£    £    £    £   
COST
At 1 January 2024 37,050 190,509 521,390 748,949
Additions - 19,650 33,000 52,650
Transfer to ownership - - (165,180 ) (165,180 )
At 31 December 2024 37,050 210,159 389,210 636,419
DEPRECIATION
At 1 January 2024 1,544 76,827 179,600 257,971
Charge for year 3,705 25,700 72,281 101,686
Transfer to ownership - - (87,763 ) (87,763 )
At 31 December 2024 5,249 102,527 164,118 271,894
NET BOOK VALUE
At 31 December 2024 31,801 107,632 225,092 364,525
At 31 December 2023 35,506 113,682 341,790 490,978

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

12. FIXED ASSET INVESTMENTS

Company
Shares in
group
undertakings
£   
COST
At 1 January 2024
and 31 December 2024 4,000,104
NET BOOK VALUE
At 31 December 2024 4,000,104
At 31 December 2023 4,000,104


13. STOCKS

Group
2024 2023
as restated
£    £   
Stocks 940,182 462,005

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2024 2023 2024 2023
as restated as restated
£    £    £    £   
Trade debtors 1,388,713 1,299,408 - -
Amounts owed by group undertakings - - 6,243,900 4,269,211
Other debtors 463,766 215,100 283,846 34,536
VAT 215,788 - - -
Prepayments and accrued income 964,198 831,240 - -
3,032,465 2,345,748 6,527,746 4,303,747

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2024 2023 2024 2023
as restated as restated
£    £    £    £   
Hire purchase contracts (see note 17) 136,713 181,801 - -
Payments on account 24,572 12,847 - -
Trade creditors 1,486,478 1,118,552 84,000 -
Social security and other taxes 138,995 166,405 - -
VAT - 45,247 - -
Other creditors 42,974 - - -
Directors' current accounts 5,635,029 4,392,102 4,870,000 4,020,000
Accruals 1,738,701 1,193,323 562,759 283,846
Deferred government grants 909 1,182 - -
9,204,371 7,111,459 5,516,759 4,303,846

16. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

Group
2024 2023
as restated
£    £   
Hire purchase contracts (see note 17) 57,119 160,252

17. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Group
Hire purchase
contracts
2024 2023
as restated
£    £   
Net obligations repayable:
Within one year 136,713 181,801
Between one and five years 57,119 160,252
193,832 342,053

Group
Non-cancellable
operating leases
2024 2023
as restated
£    £   
Within one year 741,691 866,691
Between one and five years 697,987 1,741,762
1,439,678 2,608,453

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

18. SECURED DEBTS

The following secured debts are included within creditors:

Group
2024 2023
as restated
£    £   
Hire purchase contracts 193,832 342,053

The hire purchase contracts and finance leases are secured on the underlying assets.

19. PROVISIONS FOR LIABILITIES

Group
2024 2023
as restated
£    £   
Deferred tax
Tax losses carried forward (78,927 ) (27,567 )
Other timing differences (227 ) (296 )
Accelerated capital allowances 277,883 266,503
198,729 238,640

Group
Deferred
tax
£   
Balance at 1 January 2024 238,640
Utilised during year (39,911 )
Balance at 31 December 2024 198,729

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

20. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number: Class: Nominal Value 2024 2023
NIL A Ordinary 1p - 7
NIL B Ordinary 1p - 4
75,750 A Ordinary £0.0001 0.01p 8 -
35,000 B Ordinary £0.0001 0.01p 4 -

On 8 May 2024 the existing class of 650 A Ordinary Shares of 1p each were subdivided into 65,000 A Ordinary Shares of £0.0001 each and the existing class of 350 B Ordinary Shares of 1p each were subdivided into 35,000 B Ordinary Shares of £0.0001 each .

On 8 May 2024 10,750 A Ordinary Shares of £0.0001 each were issued for consideration of £120 per share which amounts to £1,290,000 as part of a debt for equity swap.

On 18 February 2025 3,334 A Ordinary Shares of £0.0001 each were issued for consideration of £120 per share which amounts to £400,080.

Both classes of shares carry equal voting rights, rank pari passu with any ordinary shares as to rights to dividends, distributions and capital distributions. All shares are non-redeemable.

21. RESERVES

Group
Retained Share
earnings premium Totals
£    £    £   

At 1 January 2024 (2,512,941 ) 3,999,994 1,487,053
Prior year adjustment (34,536 ) (34,536 )
(2,547,477 ) 1,452,517
Deficit for the year (2,502,637 ) (2,502,637 )
Cash share issue - 2,279,949 2,279,949
At 31 December 2024 (5,050,114 ) 6,279,943 1,229,829


22. NON-CONTROLLING INTERESTS

During the year, two directors, acquired shares in a subsidiary as part of a debt for equity swap. Each director acquired 2,475 ordinary A shares of £1 each (4,950 shares in total), aggregate par value of £50, meaning they now hold a 33% non-controlling interest in the subsidiary undertaking, Bio Scope Technologies Limited. The shares acquired have full voting rights, rank pari passu with any ordinary shares as to rights to dividends, distributions and capital distributions. All shares are non-redeemable.

£ 713,231 of the loss made by the Group in 2024 is attributable to these non-controlling parties.

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

23. PENSION COMMITMENTS

The Group operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Group in an independently administered fund. The pension cost charge represents contributions payable by the Group to the fund and amounted to £213,837 (2023 £181,560). Contributions totalling £45,771 (2023 £Nil) were payable to the fund at the balance sheet date and included in creditors.

24. CAPITAL COMMITMENTS
2024 2023
as restated
£    £   
Contracted but not provided for in the
financial statements - 178,604

25. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 December 2024 and 31 December 2023:

2024 2023
as restated
£    £   
A C T Gomarsall
Balance outstanding at start of year - 267
Amounts advanced 2,634 3,962
Amounts repaid (2,634 ) (4,229 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - -

J A Gomarsall
Balance outstanding at start of year 585 1,428
Amounts advanced 3,273 4,150
Amounts repaid (3,858 ) (4,993 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - 585

26. RELATED PARTY DISCLOSURES

Interest of £602,695 (2023: £258,645) has been included in accruals for the loans from the directors. The loans are unsecured.

J A Gomarsall
Director and shareholder in parent company

The premises from which the company trades was acquired by J A Gomarsall and M Fennings, a former director of the immediate parent company, during 2012. The company has a fifteen year lease with a current rent of £242,599 per annum. During the year the total rent paid to J A Gomarsall and M Fennings was £242,599 (2023: £242,599). At the year end £40,417 (2023: £40,417) is unpaid.

During the year, J A Gomarsall advanced £150,000 to the group through the director loan. £445 of this amount was repaid in 2024 leaving a balance of £489,555 (2023: £339,415) outstanding at the year end.

Bio Scope 3 Ltd (Registered number: 13216336)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

26. RELATED PARTY DISCLOSURES - continued

N J Razey
Director and shareholder

During the year, N Razey advanced £495,000 to the group through the director loan. The outstanding balance at the year end is £2,480,000 (2023: £1,985,000).

S Taylor
Director and shareholder

During the year, S Taylor advanced £1,178,788 to the group through the director loan. £582,000 of this amount was repaid in 2024 leaving a balance of £2,663,788 (2023: £2,067,000) outstanding at the year end.

R K Edwards
Director of Network 2 Supplies Limited

During the year charges of £23,788 have been made to Network 2 Supplies Limited by Ezro Limited which is under common control. No amounts are outstanding at the year end.

27. ULTIMATE CONTROLLING PARTY

There are no individual controlling parties.

28. SHARE-BASED PAYMENT TRANSACTIONS

The company operates an Enterprise Management Incentive (EMI) scheme under which share options were granted to an employee's to incentivize and retain key staff. The valuation of the company's shares for the purpose of the EMI option grant was agreed with HMRC. The agreed fair value per share for the EMI option is £6,153.85. Options issued related to 44B Ordinary shares.

The vesting period was reached on 28 February 2024, and remain exercisable for seven years post-vesting. The options lapse if the employee resigns or are dismissed. At the balance sheet date 11 shares remain exercisable.

The fair value of the options granted has been measured at the grant date and will be accounted for in accordance with Section 26 of FRS 102 - Share-based Payment. The share-based payment expense will be recognised in the profit and loss account over the vesting period.

As there is currently no reliable basis to determine a probable valuation or timing of exercise, no expense has been recognised in the current year. The total recognised expense for the current year is £nil.